RG7598
/ Roche, Pfizer
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 07, 2019
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.
(PubMed, Blood Cancer J)
- "FcRH5 was confirmed to be expressed and occupied by antibody post-treatment and thus remains a valid myeloma target. Nevertheless, this MMAE-based antibody-drug-conjugate targeting FcRH5 was unsuccessful for myeloma."
Journal • P1 data
1 to 1
Of
1
Go to page
1